EUVIMEDEUVIMED entdecken
Crossref

Development and Characterization of a Fully Human Recombinant MPO ‐ ANCA Monoclonal Antibody as Candidate Quality Control Material

Meiyu Guo iD, Yeshuang Yuan iD, Xuan Zhang iD, Yudong Liu iD

International Journal of Rheumatic Diseases · 2026

DOI: 10.1111/1756-185x.70889 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2026. Verfasst von Meiyu Guo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Peroxidase, Antibodies, Antineutrophil Cytoplasmic. Die Arbeit nennt 17 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

MPO‐ANCA detection suffers prominent inter‐assay variability due to a shortage of standardized, sustainable quality control (QC) materials. Existing patient‐pooled sera have limited supply, while chimeric monoclonal antibodies fail to fully mimic human autoantibodies. This study aimed to construct a fully human recombinant MPO‐ANCA monoclonal antibody and systematically characterize its analytical performance as a candidate QC material for multi‐platform MPO‐ANCA immunoassay evaluation.

Methods

A human anti‐MPO scFv phage display library was constructed using peripheral blood mononuclear cells obtained from MPO‐ANCA‐positive patients. Following antigen‐specific biopanning and screening, the candidate clone H042 was selected and converted into a full‐length human IgG1 monoclonal antibody. We verified its structural integrity, antigen specificity, pANCA immunofluorescence pattern, quantitative linearity, thermal/freeze–thaw stability, and cross‐kit performance across enzyme‐linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), multiplex flow immunoassay, and indirect immunofluorescence assay (IIFA) from multiple mainstream manufacturers.

Results

Purified H042 exhibited intact IgG structure, strong MPO binding affinity, and no cross‐reactivity with PR3/GBM. It presented typical pANCA staining in IIFA and showed predictable quantitative response. H042 retained > 89% residual activity under accelerated thermal and repeated freeze–thaw stress. Notably, H042 yielded consistent qualitative positivity on all tested kits of four mainstream methodologies without false‐negative signals, despite inter‐platform signal intensity differences.

Conclusion

The fully human monoclonal antibody H042 demonstrated favorable structural integrity, MPO specificity, and broad detectability across the evaluated commercial assay platforms. These characteristics support its potential as a scalable recombinant candidate QC material and an auxiliary tool for MPO‐ANCA assay harmonization and laboratory quality assurance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalPeroxidaseAntibodies, Antineutrophil CytoplasmicHumansQuality ControlRecombinant ProteinsEnzyme-Linked Immunosorbent AssayReproducibility of ResultsPredictive Value of TestsAntibody SpecificityProtein StabilityFluorescent Antibody Technique, IndirectImmunoglobulin GBiomarkers

Stichwörter der Autor:innen

ANCA‐associated vasculitisMPO‐ANCAfully human monoclonal antibodymulti‐platform immunoassay standardizationquality control material

Substanzen

Antibodies, MonoclonalRecombinant ProteinsPeroxidaseMPO protein, humanAntibodies, Antineutrophil CytoplasmicImmunoglobulin GBiomarkers

Autor:innen und Institutionen

  • Department of Rheumatology, Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC, Institute of Geriatric Medicine, Chinese Academy…
  • National Center for Clinical Laboratories, Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC, Institute of Geriatric Medicine,…

ORCID-Profile: Meiyu Guo, Yeshuang Yuan, Xuan Zhang, Yudong Liu

Förderung

  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Guo, M., Yuan, Y., Zhang, X., & Liu, Y. (2026). Development and Characterization of a Fully Human Recombinant MPO ‐ ANCA Monoclonal Antibody as Candidate Quality Control Material. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70889

Vancouver

Guo M, Yuan Y, Zhang X, Liu Y. Development and Characterization of a Fully Human Recombinant MPO ‐ ANCA Monoclonal Antibody as Candidate Quality Control Material. International Journal of Rheumatic Diseases. 2026. doi:10.1111/1756-185x.70889

BibTeX
@article{Guo2026,
  author = {Guo, Meiyu and Yuan, Yeshuang and Zhang, Xuan and Liu, Yudong},
  title = {Development and Characterization of a Fully Human Recombinant MPO ‐ ANCA Monoclonal Antibody as Candidate Quality Control Material},
  journal = {International Journal of Rheumatic Diseases},
  year = {2026},
  doi = {10.1111/1756-185x.70889}
}
Kostenlos starten →